BriaCell Therapeutics Corp.
BCTX
$2.02
-$0.05-2.42%
NASDAQ
| 04/30/2025 | 01/31/2025 | 10/31/2024 | 07/31/2024 | 04/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 1.63M | 1.60M | 1.60M | 1.55M | 1.68M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 6.33M | 7.17M | 5.15M | 5.77M | 9.23M |
| Operating Income | -6.33M | -7.17M | -5.15M | -5.77M | -9.23M |
| Income Before Tax | -6.22M | -6.34M | -5.83M | -1.25M | 1.69M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -6.22M | -6.34M | -5.83M | -1.25M | 1.69M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 98.00K | 46.40K | 27.10K | 34.60K | 23.50K |
| Net Income | -6.13M | -6.29M | -5.80M | -1.21M | 1.72M |
| EBIT | -6.33M | -7.17M | -5.15M | -5.77M | -9.23M |
| EBITDA | -6.30M | -7.14M | -5.13M | -5.70M | -9.23M |
| EPS Basic | -1.64 | -2.33 | -3.27 | -1.02 | 1.61 |
| Normalized Basic EPS | -1.02 | -1.45 | -2.04 | -0.63 | 1.01 |
| EPS Diluted | -1.64 | -2.33 | -3.30 | -1.07 | 1.61 |
| Normalized Diluted EPS | -1.02 | -1.45 | -2.04 | -0.63 | 1.01 |
| Average Basic Shares Outstanding | 3.74M | 2.70M | 1.78M | 1.19M | 1.07M |
| Average Diluted Shares Outstanding | 3.74M | 2.70M | 1.78M | 1.19M | 1.07M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |